Page last updated: 2024-11-01
omeprazole and Ache
omeprazole has been researched along with Ache in 36 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia." | 9.69 | Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial. ( Angsusing, J; Buamahakul, T; Chumsri, C; Khamsai, S; Khongkha, W; Kongkam, P; Kosarussawadee, P; Lopimpisuth, C; Phisalprapa, P; Phutrakool, P; Pongpirul, K; Poonniam, P; Sawanyawisuth, K; Siwamogsatham, S; Sura, T; Teerachaisakul, M; Wanaratna, K, 2023) |
| "In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD)." | 9.11 | Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. ( Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E, 2005) |
| "In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0." | 9.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
| "The purpose of this multicenter, randomized, double-blind study, conducted in 520 patients, was to compare the efficacy and safety of omeprazole (40 and 20 mg once daily) with placebo in the treatment of benign gastric ulcer." | 9.08 | Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study. ( Colón Pagán, JR; Gilde, LR; Kogut, DG; McCullough, AJ; Shah, U; Simon, TJ; Valenzuela, JE; Whipple, J, 1996) |
| "In this randomized, double-blind, multicentre study, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers." | 9.08 | Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1998) |
| "The proton pump inhibitors pantoprazole and omeprazole were compared in a randomized, double-blind study in 219 patients with benign gastric ulcers." | 9.08 | Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. ( Gütz, H; Hüttemann, W; Schepp, W; Witzel, L, 1995) |
| "In a Swedish-Norwegian multicentre study patients with endoscopically verified duodenal ulcers (greater than 5 mm) were randomized to 2 or 4 weeks of treatment with either 20 mg omeprazole once daily or 300 mg ranitidine once daily." | 9.07 | Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research. ( Carling, L; Engström, G; Glise, H; Hallerbäck, B; Martinson, J; Solhaug, JH; Unge, P, 1991) |
| "The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial." | 9.07 | [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. ( Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL, 1993) |
| "To assess the comparative efficacy of omeprazole 20 mg in the morning versus ranitidine 150 mg twice a day, in the healing of duodenal ulcer, 43 endoscopically verified cases were randomly allocated to 2 or 4 weeks (if ulcer did not heal at 2 weeks) treatment." | 9.07 | Omeprazole vs ranitidine in the healing of duodenal ulcer. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1993) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "We conducted a double-blind, randomized, parallel group study in 169 patients with acute duodenal ulcers to compare omeprazole, 20 mg daily, with cimetidine, 600 mg twice daily." | 9.06 | Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. ( Archambault, AP; Bailey, RJ; Baker, SJ; Freeman, HJ; Hunt, RH; Marcon, NE; Navert, H; Pare, P; Sutherland, L; Williams, CN, 1988) |
| "The object of this double-blind, multicentre study was to compare duodenal ulcer healing rates after 2 to 4 weeks of treatment with either 20 mg omeprazole o." | 9.06 | Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. ( Cluysenaer, OJ; Gerrits, C; Hazenberg, BP; Meyer, WW; Mulder, CJ; Nicolai, JJ; Stuifbergen, WH; Tijtgat, GN; Vogten, AJ, 1989) |
| "One-hundred and seventy-one patients with endoscopically proven duodenal ulcers were allocated at random to double-blind treatment with 10 or 20 mg of omeprazole in the morning for up to 4 weeks." | 9.06 | Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Jørgensen, T; Lauritsen, K; Laursen, LS; Rask-Madsen, J, 1989) |
| "We conducted a double-blind randomized study of 132 patients to determine whether the new, investigational proton-pump inhibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer." | 9.05 | Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. ( Andersen, HH; Bendtsen, F; Bytzer, P; Højlund, M; Jensen, KG; Kelbaek, H; Lauritsen, K; Linde, J; Rask-Madsen, J; Rune, SJ, 1985) |
| "Our data suggest that the opioid system, particularly beta-endorphin, is involved in the perception of pain in duodenal ulcer disease, which explains the silent clinical characteristics of some peptic ulcers." | 7.69 | Beta-endorphin in silent duodenal ulcer. ( Chianelli, M; Delle Fave, G; Mariani, P; Negri, M; Tonnarini, GF, 1995) |
| "To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia." | 5.69 | Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial. ( Angsusing, J; Buamahakul, T; Chumsri, C; Khamsai, S; Khongkha, W; Kongkam, P; Kosarussawadee, P; Lopimpisuth, C; Phisalprapa, P; Phutrakool, P; Pongpirul, K; Poonniam, P; Sawanyawisuth, K; Siwamogsatham, S; Sura, T; Teerachaisakul, M; Wanaratna, K, 2023) |
| "In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD)." | 5.11 | Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. ( Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E, 2005) |
| "In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0." | 5.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
| " Treating duodenal ulcer with simultaneous administration of omeprazole achieves ulcer pain relief more rapidly." | 5.09 | Does eradication of Helicobacter pylori alone heal duodenal ulcers? ( Chen, Y; Ge, ZZ; Hu, YB; Xiao, SD; Zhang, DZ, 2000) |
| "In this randomized, double-blind, multicentre study, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers." | 5.08 | Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1998) |
| "The purpose of this multicenter, randomized, double-blind study, conducted in 520 patients, was to compare the efficacy and safety of omeprazole (40 and 20 mg once daily) with placebo in the treatment of benign gastric ulcer." | 5.08 | Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study. ( Colón Pagán, JR; Gilde, LR; Kogut, DG; McCullough, AJ; Shah, U; Simon, TJ; Valenzuela, JE; Whipple, J, 1996) |
| "The proton pump inhibitors pantoprazole and omeprazole were compared in a randomized, double-blind study in 219 patients with benign gastric ulcers." | 5.08 | Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. ( Gütz, H; Hüttemann, W; Schepp, W; Witzel, L, 1995) |
| "To assess the comparative efficacy of omeprazole 20 mg in the morning versus ranitidine 150 mg twice a day, in the healing of duodenal ulcer, 43 endoscopically verified cases were randomly allocated to 2 or 4 weeks (if ulcer did not heal at 2 weeks) treatment." | 5.07 | Omeprazole vs ranitidine in the healing of duodenal ulcer. ( Ahmed, W; Alam, SE; Qureshi, H; Zuberi, SJ, 1993) |
| "In a Swedish-Norwegian multicentre study patients with endoscopically verified duodenal ulcers (greater than 5 mm) were randomized to 2 or 4 weeks of treatment with either 20 mg omeprazole once daily or 300 mg ranitidine once daily." | 5.07 | Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research. ( Carling, L; Engström, G; Glise, H; Hallerbäck, B; Martinson, J; Solhaug, JH; Unge, P, 1991) |
| "The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial." | 5.07 | [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. ( Andrieu, J; Coste, T; Dupuis, J; Grimaud, JC; Julien, H; Lemerez, M; Licht, H; Petite, JP; Sallerin, V; Slama, JL, 1993) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "One-hundred and seventy-one patients with endoscopically proven duodenal ulcers were allocated at random to double-blind treatment with 10 or 20 mg of omeprazole in the morning for up to 4 weeks." | 5.06 | Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial. ( Andersen, BN; Eriksen, J; Hansen, J; Havelund, T; Jørgensen, T; Lauritsen, K; Laursen, LS; Rask-Madsen, J, 1989) |
| "Endoscopic evidence of accelerated healing of type I gastric ulcers after four weeks of omeprazole." | 5.06 | Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: a double blind comparative trial. Danish Omeprazole Study Group. ( , 1989) |
| "The object of this double-blind, multicentre study was to compare duodenal ulcer healing rates after 2 to 4 weeks of treatment with either 20 mg omeprazole o." | 5.06 | Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. ( Cluysenaer, OJ; Gerrits, C; Hazenberg, BP; Meyer, WW; Mulder, CJ; Nicolai, JJ; Stuifbergen, WH; Tijtgat, GN; Vogten, AJ, 1989) |
| "We conducted a double-blind, randomized, parallel group study in 169 patients with acute duodenal ulcers to compare omeprazole, 20 mg daily, with cimetidine, 600 mg twice daily." | 5.06 | Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. ( Archambault, AP; Bailey, RJ; Baker, SJ; Freeman, HJ; Hunt, RH; Marcon, NE; Navert, H; Pare, P; Sutherland, L; Williams, CN, 1988) |
| "We conducted a double-blind randomized study of 132 patients to determine whether the new, investigational proton-pump inhibitor, omeprazole (30 mg per day), would accelerate healing and pain relief, as compared with cimetidine (1 g per day), in patients with duodenal ulcer." | 5.05 | Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. ( Andersen, HH; Bendtsen, F; Bytzer, P; Højlund, M; Jensen, KG; Kelbaek, H; Lauritsen, K; Linde, J; Rask-Madsen, J; Rune, SJ, 1985) |
| " The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
| "Our data suggest that the opioid system, particularly beta-endorphin, is involved in the perception of pain in duodenal ulcer disease, which explains the silent clinical characteristics of some peptic ulcers." | 3.69 | Beta-endorphin in silent duodenal ulcer. ( Chianelli, M; Delle Fave, G; Mariani, P; Negri, M; Tonnarini, GF, 1995) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| "Lansoprazole or ranitidine was given to 133 patients for 4-8 weeks in a double-blind, randomized, parallel group, multicentre trial." | 2.69 | Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. ( Jansen, JB; Van Oene, JC, 1999) |
| "Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors." | 1.31 | Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002) |
Research
Studies (36)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.67) | 18.7374 |
| 1990's | 13 (36.11) | 18.2507 |
| 2000's | 11 (30.56) | 29.6817 |
| 2010's | 2 (5.56) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Yongwatana, K | 1 |
| Harinwan, K | 1 |
| Chirapongsathorn, S | 1 |
| Opuchar, K | 1 |
| Sanpajit, T | 1 |
| Piyanirun, W | 1 |
| Puttapitakpong, C | 1 |
| Truong, TM | 1 |
| Apfelbaum, JL | 1 |
| Danahey, K | 1 |
| Schierer, E | 1 |
| Ludwig, J | 1 |
| George, D | 1 |
| House, L | 1 |
| Karrison, T | 1 |
| Shahul, S | 1 |
| Anitescu, M | 1 |
| Choksi, A | 1 |
| Hartman, S | 1 |
| Knoebel, RW | 1 |
| van Wijk, XMR | 1 |
| Yeo, KJ | 1 |
| Meltzer, DO | 1 |
| Ratain, MJ | 1 |
| O'Donnell, PH | 1 |
| Kongkam, P | 1 |
| Khongkha, W | 1 |
| Lopimpisuth, C | 1 |
| Chumsri, C | 1 |
| Kosarussawadee, P | 1 |
| Phutrakool, P | 1 |
| Khamsai, S | 1 |
| Sawanyawisuth, K | 1 |
| Sura, T | 1 |
| Phisalprapa, P | 1 |
| Buamahakul, T | 1 |
| Siwamogsatham, S | 1 |
| Angsusing, J | 1 |
| Poonniam, P | 1 |
| Wanaratna, K | 1 |
| Teerachaisakul, M | 1 |
| Pongpirul, K | 1 |
| Korff, CP | 1 |
| Williamson, BG | 1 |
| Goswami, SK | 1 |
| Inceoglu, B | 1 |
| Yang, J | 1 |
| Wan, D | 1 |
| Kodani, SD | 1 |
| da Silva, CA | 1 |
| Morisseau, C | 1 |
| Hammock, BD | 1 |
| Vaduganathan, M | 1 |
| Bhatt, DL | 1 |
| Cryer, BL | 1 |
| Liu, Y | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Cannon, CP | 1 |
| Prasad, R | 1 |
| De Silva, M | 1 |
| Labenz, J | 1 |
| Blum, AL | 1 |
| Bolten, WW | 1 |
| Dragosics, B | 1 |
| Rösch, W | 1 |
| Stolte, M | 1 |
| Koelz, HR | 1 |
| Laheij, RJ | 1 |
| Van Rossum, LG | 1 |
| Jansen, JB | 2 |
| Verheugt, FW | 1 |
| Osipenko, MF | 1 |
| Venzhina, IuIu | 1 |
| Dohmen, W | 1 |
| Fuchs, W | 1 |
| Archimandritis, AJ | 1 |
| Nikolopoulou, V | 1 |
| Kouklakis, G | 1 |
| Paraskevas, E | 1 |
| Avgerinos, A | 1 |
| Tsianos, E | 1 |
| Triantafillidis, JK | 1 |
| Ulualp, S | 1 |
| Brodsky, L | 1 |
| Jerome, L | 1 |
| Tonnarini, GF | 1 |
| Delle Fave, G | 1 |
| Chianelli, M | 1 |
| Mariani, P | 1 |
| Negri, M | 1 |
| Witzel, L | 1 |
| Gütz, H | 1 |
| Hüttemann, W | 1 |
| Schepp, W | 1 |
| Hosking, SW | 1 |
| Ling, TK | 1 |
| Chung, SC | 1 |
| Yung, MY | 1 |
| Cheng, AF | 1 |
| Sung, JJ | 1 |
| Li, AK | 1 |
| Arber, N | 1 |
| Avni, Y | 1 |
| Eliakim, R | 1 |
| Swissa, A | 1 |
| Melzer, E | 1 |
| Rachmilewitz, D | 1 |
| Konikoff, F | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| Sharma, MP | 1 |
| Petite, JP | 1 |
| Slama, JL | 1 |
| Licht, H | 1 |
| Lemerez, M | 1 |
| Coste, T | 1 |
| Andrieu, J | 1 |
| Grimaud, JC | 1 |
| Julien, H | 1 |
| Dupuis, J | 1 |
| Sallerin, V | 1 |
| Ahmed, W | 1 |
| Qureshi, H | 1 |
| Zuberi, SJ | 1 |
| Alam, SE | 1 |
| Valenzuela, JE | 1 |
| Kogut, DG | 1 |
| McCullough, AJ | 1 |
| Colón Pagán, JR | 1 |
| Shah, U | 1 |
| Whipple, J | 1 |
| Gilde, LR | 1 |
| Simon, TJ | 1 |
| Dekkers, CP | 1 |
| Beker, JA | 1 |
| Thjodleifsson, B | 1 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Humphries, TJ | 1 |
| Jones, R | 1 |
| Crouch, SL | 1 |
| Van Oene, JC | 1 |
| Ge, ZZ | 1 |
| Zhang, DZ | 1 |
| Xiao, SD | 1 |
| Chen, Y | 1 |
| Hu, YB | 1 |
| Dupas, JL | 1 |
| Houcke, P | 1 |
| Samoyeau, R | 1 |
| Tröger, U | 1 |
| Stötzel, B | 1 |
| Martens-Lobenhoffer, J | 1 |
| Gollnick, H | 1 |
| Meyer, FP | 1 |
| Convens, C | 1 |
| Verhelst, J | 1 |
| Mahler, C | 1 |
| Glise, H | 1 |
| Martinson, J | 1 |
| Solhaug, JH | 1 |
| Carling, L | 1 |
| Unge, P | 1 |
| Engström, G | 1 |
| Hallerbäck, B | 1 |
| Lauritsen, K | 2 |
| Andersen, BN | 1 |
| Havelund, T | 1 |
| Laursen, LS | 1 |
| Hansen, J | 1 |
| Eriksen, J | 1 |
| Jørgensen, T | 1 |
| Rask-Madsen, J | 2 |
| Mulder, CJ | 1 |
| Tijtgat, GN | 1 |
| Cluysenaer, OJ | 1 |
| Nicolai, JJ | 1 |
| Meyer, WW | 1 |
| Hazenberg, BP | 1 |
| Vogten, AJ | 1 |
| Gerrits, C | 1 |
| Stuifbergen, WH | 1 |
| Archambault, AP | 1 |
| Pare, P | 1 |
| Bailey, RJ | 1 |
| Navert, H | 1 |
| Williams, CN | 1 |
| Freeman, HJ | 1 |
| Baker, SJ | 1 |
| Marcon, NE | 1 |
| Hunt, RH | 1 |
| Sutherland, L | 1 |
| Rune, SJ | 1 |
| Bytzer, P | 1 |
| Kelbaek, H | 1 |
| Jensen, KG | 1 |
| Bendtsen, F | 1 |
| Linde, J | 1 |
| Højlund, M | 1 |
| Andersen, HH | 1 |
| Spiro, HM | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care[NCT03729180] | 1,900 participants (Anticipated) | Interventional | 2019-01-22 | Recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
25 trials available for omeprazole and Ache
| Article | Year |
|---|---|
Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
Topics: Curcuma; Curcumin; Double-Blind Method; Dyspepsia; Humans; Omeprazole; Pain; Quality of Life; Treatm | 2022 |
Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.
Topics: Female; Humans; Hydralazine; Male; Omeprazole; Oxycodone; Pain; Pantoprazole; Perioperative Care; Ph | 2022 |
Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial.
Topics: Adult; Curcumin; Dyspepsia; Female; Humans; Middle Aged; Omeprazole; Pain; Proton Pump Inhibitors | 2023 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dicl | 2002 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2005 |
Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 | 1995 |
Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.
Topics: Adult; Aged; Antacids; Biopsy; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer | 1994 |
A multicenter, double-blind, randomized controlled study of omeprazole versus ranitidine in the treatment of duodenal ulcer in Israel.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Isra | 1994 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
[Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Double-Blin | 1993 |
Omeprazole vs ranitidine in the healing of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Female; Humans; Male; Middle | 1993 |
Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study.
Topics: Double-Blind Method; Drug Administration Schedule; Humans; Middle Aged; Omeprazole; Pain; Patient Co | 1996 |
Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 1998 |
Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Eructati | 1999 |
Does eradication of Helicobacter pylori alone heal duodenal ulcers?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobac | 2000 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scandinavian Clinics for United Research.
Topics: Absenteeism; Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antacids; Drug Administrati | 1991 |
Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double-blind comparative trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Humans; Mal | 1989 |
Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: a double blind comparative trial. Danish Omeprazole Study Group.
Topics: Aged; Cimetidine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1989 |
Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief.
Topics: Adult; Aged; Antacids; Double-Blind Method; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Omepr | 1989 |
Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief.
Topics: Adult; Aged; Antacids; Cimetidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admin | 1988 |
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Clinical Trials as Topic; Double-Blind M | 1985 |
Other Studies
11 other studies available for omeprazole and Ache
| Article | Year |
|---|---|
Clinical Presentation of Chiari-like Malformation in 2 Persian Cats.
Topics: Aggression; Animals; Anxiety; Arnold-Chiari Malformation; Brain; Cat Diseases; Cats; Craniosynostose | 2020 |
Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.
Topics: Analgesics; Animals; Cytochrome P-450 Enzyme System; Dinoprostone; Enzyme Inhibitors; Epoxide Hydrol | 2015 |
Osteoporosis with underlying connective tissue disease: an unusual case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Ant | 2002 |
[Problems of excretory insufficiency of the pancreas].
Topics: Adolescent; Adult; Aged; Famotidine; Feces; Female; Histamine H2 Antagonists; Humans; Male; Middle A | 2004 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazol | 2005 |
Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child, Preschool; Diet; Gastroesophageal | 2005 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Beta-endorphin in silent duodenal ulcer.
Topics: Adult; beta-Endorphin; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Nociceptors; Omeprazole; P | 1995 |
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Benzimidazoles; Dermatologic Agents; Dru | 2002 |
Painful gynaecomastia during omeprazole therapy.
Topics: Aged; Drug Administration Schedule; Esophagitis, Peptic; Gynecomastia; Humans; Male; Omeprazole; Pai | 1991 |
Duodenal ulcer disease.
Topics: Anti-Ulcer Agents; Benzimidazoles; Campylobacter Infections; Cimetidine; Duodenal Ulcer; Duodenoscop | 1985 |